Biologics like omalizumab, an anti-immunoglobulin E (anti-IgE) monoclonal antibody, may be effective in treating CRSwNP with comorbid asthma as this systemic therapy might be useful to simultaneously control upper and lower respiratory disease [75]. The gene discussed is IGHE; the disease is chronic rhinosinusitis with nasal polyps.